null

Mogamulizumab (Anti-CD194 / CCR4) Biosimilar In Vivo Antibody (Fc Reduced)

SKU:
IVMB0205
Product Type:
Biosimilar In Vivo Antibody
Protein:
CD194
Clone:
KW-0761
Isotype:
IgG1 kappa
Reactivity:
Human
Synonyms:
CD194, CKR-4, CCR-4, CCR4, K5-5
€579
Frequently bought together:

Description

system_update_altDatasheet
Product Name:Mogamulizumab (Anti-CD194 / CCR4) Biosimilar In Vivo Antibody (Fc Reduced)
Product Code:IVMB0205
Clone:KW-0761
Protein:CD194
Product Type:Biosimilar Recombinant Human Monoclonal Antibody
Synonyms:CD194, CKR-4, CCR-4, CCR4, K5-5
Isotype:Human IgG1κ
Reactivity:Human
Immunogen:Humanization of mouse anti-CCR4 mAb7.
Applications:Depletion, ELISA, FA, FC
Formulation:This biosimilar antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
Endotoxin Level:< 1.0 EU/mg as determined by the LAL method
Purity:≥95% monomer by analytical SEC
Preparation:Functional grade preclinical antibodies are manufactured in an animal free facility using only In vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.
Storage and Handling:Functional grade biosimilar antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.
Applications:Depletion, ELISA, FA, FC
Recommended Usage:FC
The suggested concentration for Mogamulizumab biosimilar antibody for staining cells in flow cytometry is ≤ 0.25 µg per 106 in a volume of 100 µl. Titration of the reagent is recommended for optimal performance for each application.
Reactivity:Human
Specificity:This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Mogamulizumab. Clone KW-0761 recognizes human CD194 (CCR4). This product is for research use only.
Antigen Distribution:CCR4 is primarily expressed by Th2 and regulatory T cells in addition to expression on leukemic cells in cutaneous T-cell lymphoma (CTCL).
Immunogen:Humanization of mouse anti-CCR4 mAb7.
Concentration:≥ 5.0 mg/ml
Endotoxin Level:< 1.0 EU/mg as determined by the LAL method
Purity:≥95% monomer by analytical SEC
Formulation:This biosimilar antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
Preparation:Functional grade preclinical antibodies are manufactured in an animal free facility using only In vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.
Storage and Handling:Functional grade biosimilar antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.
Clone KW-0761 (Mogamulizumab) is a research-grade, afucosylated, humanized monoclonal antibody generated from mouse anti-CCR4 mAb7 that targets human CCR4.1 CC chemokine receptor type 4 (CCR4) is a protein that belongs to the G protein-coupled receptor family and is a receptor for a variety of CC chemokines including MCP-1, MIP-1, RANTES, TARC, and Macrophage-derived chemokine. Chemokines are involved in the development, homeostasis, and function of the immune system and are known to regulate cell trafficking of various types of leukocytes. In a 2018 Phase I clinical trial, Mogamulizumab was found to decrease the number of HTLV-1�infected cells and the levels of inflammatory markers related to HTLV-1�Associated Myelopathy.3
Protein:CD194
Research Area:Immunology, Innate Immunity, Stem Cell

Related Products